#Nephrology #Dialysis #Semaglutide #GLP1 #Diabetes #Cardiovascular #EASD2025 #PatientSafety #MedicalResearch To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)
Treatment of Growth Hormone Deficiency While aging is not a disease, it results in significantly maladaptive changes in body composition and function which affect the individual and the community at large
Much of our knowledge surrounding the MC3R derives from studies involving MC3R KO animals, which demonstrate increased adiposity, reduced lean mass, and increased feed efficiency, with mildly reduced or absent changes in caloric intake and normal metabolic rates (Butler et al., 2000
"The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials." Clin Nutr ESPEN
Some patients can have amounts of oats and citrus without any problems
Beyond its role as a protector, glutathione helps support the bodys natural detoxification pathways
